Study of abemaciclib safety for breast cancer patients
Part of Cancer, Skin clinical trials.
This study looks at real-world safety and side effect management of abemaciclib combined with hormone therapy for patients with RH+, HER2- breast cancer. It aims to understand how well patients tolerate treatment outside of clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have been treated with abemaciclib after surgery along with hormone therapy.
- You have a type of breast cancer called RH+ and HER2- (meaning your cancer cells have receptors for hormones but not too much HER2 protein).
- Your cancer had spread to at least 4 lymph nodes under the arm, or it had spread to 1 to 3 lymph nodes if the tumor was grade 3 (more aggressive) or larger than 5 cm.
- You are not under legal guardianship or trusteeship.
- You agree to take part in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with hormone receptor-positive breast cancer who are at high risk of recurrence. It looks at how the body processes abemaciclib, a targeted therapy, and whether that affects severe diarrhea, a common side effect.
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
This study uses real-world health records to learn about outcomes in people with hormone-receptor positive, HER2-negative breast cancer who were treated with abemaciclib along with hormone (endocrine) therapy. It may help doctors better understand how well this treatment works outside of clinical trials.
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
This study tests whether gradually increasing doses of a drug called abemaciclib, combined with hormone therapy, can safely treat early-stage breast cancer that is hormone-positive and HER2-negative. The goal is to find the best dose that works without causing too many side effects.
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
Hear when a new Brest Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.